-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
AzddMeC
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/87190-79-2.gif)
| Category | Reverse Transcriptases (RTs) |
| CAS | 87190-79-2 |
| Description | Az-Dcme is a RNA-directed DNA polymerase inhibitor potentially for the treatment of HIV infection. |
Product Information
| Synonyms | Az-Dcme; 3'-Azido-2',3'-dideoxy-5-methylcytidine; AZ-5MeC; 3'-N3-5-Me-ddC; CS-92 |
| IUPAC Name | 4-amino-1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one |
| Molecular Weight | 266.26 |
| Molecular Formula | C10H14N6O3 |
| Canonical SMILES | CC1=CN(C(=O)N=C1N)C2CC(C(O2)CO)N=[N+]=[N-] |
| InChI | InChI=1S/C10H14N6O3/c1-5-3-16(10(18)13-9(5)11)8-2-6(14-15-12)7(4-17)19-8/h3,6-8,17H,2,4H2,1H3,(H2,11,13,18)/t6-,7+,8+/m0/s1 |
| InChIKey | GZSDAHQGNUAEBC-XLPZGREQSA-N |
| Purity | >98.00% |
| Solubility | In Vitro: DMSO : 200 mg/mL(751.15 mM;Need ultrasonic) |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Complexity | 496 |
| Exact Mass | 266.112732 |
| In Vitro | AzddMeC (CS-92) is effective against HIV-2 in lymphocytes. The replication of Friend murine virus is only weakly inhibited, and no effect is observed against HSV type 1 and type 2 and coxsackievirus B4. The interaction of the 5'-triphosphate of AzddMeC with HIV-1 reverse transcriptase indicated competitive inhibition (the inhibition constant, Kis, is 9.3 nM). |
| In Vivo | The pharmacokinetics of AzddMeC are characterized following intravenous and oral administration of 60 mg/kg of the compound to male rhesus monkeys. 3'-azido-3'-deoxythymidine (AZT) is a major metabolite of AzddMeC in monkeys. AzddMeC concentrations in serum declined rapidly in a biexponential fashion with the terminal half-life ranging from 0.5 to 1.3 hr. Renal excretion of unchanged nucleoside and Metabolic deamination yielding AZT are the primary routes of AzddMeC clearance. The oral bioavailability is 26%. |
| PSA | 141.11000 |
| Target | HIV; Reverse Transcriptase; Nucleoside Antimetabolite/Analog |
| XLogP3-AA | -0.3 |
